Chimerix, Inc. (CMRX) | Investment Case

1. Company Snapshot

1.a. Company Description

Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases.The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy.

The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc.to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications.Chimerix, Inc.

was incorporated in 2000 and is headquartered in Durham, North Carolina.

Show Full description

1.b. Last Insights on CMRX

The recent stock performance of Chimerix, Inc. has been driven by several positive factors. The company's stock surged 324% in three months following the submission of its NDA for high-grade glioma drug, dordaviprone, for accelerated approval in the United States. This significant increase in stock price is a strong indication of investor confidence in the company's prospects. Additionally, the proposed acquisition of Chimerix by Jazz Pharmaceuticals plc for $8.55 per share in cash has put the company in the spotlight, with several law firms investigating the adequacy of the price and process.

1.c. Company Highlights

Last Price	8.54
Change Percentage	0.00%
Open	8.54
Previous Close	8.54
Market Cap ( Millions)	801
Volume	2552273
Year High	8.55
Year Low	0.75
M A 50	6.67
M A 200	2.75

FCF Yield	-7.21%
Dividend Yield	0.00%
ROE	-48.31%
Debt / Equity	0.38%
Net Debt / EBIDTA	42.43%
Price To Book	6.33
Price Earnings Ratio	-11.59
Price To FCF	-13.87
Price To sales	3778.7
EV / EBITDA	-10.69

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Jazz Pharmaceuticals Completes Acquisition of Chimerix

Apr -21

Source: prnewswire.com

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

Mar -31

Source: seekingalpha.com

Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

Mar -21

Source: globenewswire.com

CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX

Mar -11

Source: businesswire.com

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar -07

Source: globenewswire.com

CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders

Mar -07

Source: globenewswire.com

The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals

Mar -07

Source: zacks.com

Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More

Mar -06

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

Pharmaceuticals

Expected Growth: 10.3%

Growing demand for antiviral therapeutics, increasing prevalence of life-threatening viral infections, and Chimerix's pipeline of innovative products, including brincidofovir, are expected to drive the company's growth.

7. Detailed Products

Tembexa

An oral antiviral medication for the treatment of smallpox, which is a highly contagious and potentially life-threatening disease.

Brincidofovir

An oral antiviral medication for the treatment of adenovirus infections, which can cause severe and life-threatening diseases in immunocompromised patients.

CMX521

A novel, oral antiviral medication for the treatment of norovirus infections, which are a leading cause of gastroenteritis worldwide.

CMX157

A novel, oral antiviral medication for the treatment of HIV infections, which can cause AIDS and other life-threatening diseases.

8. Chimerix, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Chimerix, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for viral diseases.

Bargaining Power Of Customers

Chimerix, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients.

Bargaining Power Of Suppliers

Chimerix, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials.

Threat Of New Entrants

Chimerix, Inc. has a high threat of new entrants due to the attractiveness of the biotechnology industry and the availability of funding for startups.

Intensity Of Rivalry

Chimerix, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	0.50%
Debt Cost	3.95%
Equity Weight	99.50%
Equity Cost	9.57%
WACC	9.54%
Leverage	0.50%

11. Quality Control: Chimerix, Inc. passed 4 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Chimerix

A-Score: 3.3/10

Value: 6.2

Growth: 3.7

Quality: 5.0

Yield: 0.0

Momentum: 5.0

Volatility: 0.0

1-Year Total Return ->

Agenus

A-Score: 3.2/10

Value: 9.4

Growth: 2.1

Quality: 4.6

Yield: 0.0

Momentum: 2.5

Volatility: 0.7

1-Year Total Return ->

Arcus Biosciences

A-Score: 3.2/10

Value: 6.6

Growth: 3.6

Quality: 4.8

Yield: 0.0

Momentum: 1.5

Volatility: 2.7

1-Year Total Return ->

Fate Therapeutics

A-Score: 2.9/10

Value: 7.8

Growth: 4.0

Quality: 4.3

Yield: 0.0

Momentum: 0.5

Volatility: 0.7

1-Year Total Return ->

Lexicon Pharmaceuticals

A-Score: 2.8/10

Value: 6.6

Growth: 3.2

Quality: 4.4

Yield: 0.0

Momentum: 2.0

Volatility: 0.3

1-Year Total Return ->

Palatin Technologies

A-Score: 2.4/10

Value: 8.2

Growth: 0.0

Quality: 6.0

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

25.66%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

9.54%

Chimerix, Inc. - US16934W1062

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on CMRX

1.c. Company Highlights

Stable Momentum

Average Quality

Average Growth

Earnings Miss

Fairly Valued

Revenues Beats

Revenues Miss

Higher Growth

More Volatile

Strong Momentum

Earnings Beats

Average Yield

Medium Volatility

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

Pharmaceuticals

Expected Growth: 10.3%

7. Detailed Products

Tembexa

Brincidofovir

CMX521

CMX157

8. Chimerix, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Chimerix, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

8.54$

Current Price

8.54$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA